» Articles » PMID: 36341340

Bioengineering and Computational Analysis of Programmed Cell Death Ligand-1 Monoclonal Antibody

Overview
Journal Front Immunol
Date 2022 Nov 7
PMID 36341340
Authors
Affiliations
Soon will be listed here.
Abstract

The trans-membrane proteins of the B7 family programmed cell death ligand-1 (PD-L1) and programmed death-1 (PD-1) play important roles in inhibiting immune responses and enhancing self-tolerance T-cell modulation. Several therapeutic antibodies are used to promote T-cell proliferation by preventing interactions between PD-1/PD-L1. Recombinant technology appears to be quite useful in the production of such potent antibodies. In this study, we constructed recombinant molecules by cloning variable regions of the PD-L1 molecule into pMH3 vectors and transferring them into mammalian cell lines for expression. G418 supplementation was used to screen the recombinant clones, which were then maintained on serum-free medium. The full-length antibody was isolated and purified from the medium supernatant at a concentration of 0.5-0.8 mg/ml. Antibody binding affinity was investigated using ELISA and immunofluorescence methods. The protein-protein interactions (PPI) were determined using a docking approach. The SWISS model was utilized for homology modeling, while ZDOCK, Chimera, and PyMOL were used to validate 3D models. The Ramachandran plots were constructed using the SWISS model, which revealed that high-quality structures had a value of more than 90%. Current technologies allow for the accurate determination of antigen-antibody interactions.

Citing Articles

Human Tyrosinase Displayed on the Surface of Chinese Hamster Ovary Cells for Ligand Fishing of Tyrosinase Inhibitors from Medicinal Plants.

Zhai X, Li M, Yin X, Ablat A, Wang Y, Shu P Molecules. 2025; 30(1.

PMID: 39795088 PMC: 11721096. DOI: 10.3390/molecules30010030.


Effective control of postoperative recurrence of pregnancy-related gastric cancer using anti-PD-1 as a monotherapy: a case report.

Liu X, Li X, Zhu C, Ji L Front Oncol. 2024; 14:1321149.

PMID: 38800370 PMC: 11116784. DOI: 10.3389/fonc.2024.1321149.


Tissue-type plasminogen activator (tPA) homozygous Tyr471His mutation associates with thromboembolic disease.

Tao Y, Ma J, Feng Y, Gao C, Wu T, Xia Y MedComm (2020). 2023; 4(5):e392.

PMID: 37808270 PMC: 10556205. DOI: 10.1002/mco2.392.

References
1.
Redman J, Hill E, AlDeghaither D, Weiner L . Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol. 2015; 67(2 Pt A):28-45. PMC: 4529810. DOI: 10.1016/j.molimm.2015.04.002. View

2.
Holliger P, Hudson P . Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005; 23(9):1126-36. DOI: 10.1038/nbt1142. View

3.
Butte M, Keir M, Phamduy T, Sharpe A, Freeman G . Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007; 27(1):111-22. PMC: 2707944. DOI: 10.1016/j.immuni.2007.05.016. View

4.
Chames P, van Regenmortel M, Weiss E, Baty D . Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009; 157(2):220-33. PMC: 2697811. DOI: 10.1111/j.1476-5381.2009.00190.x. View

5.
Weng G, Wang E, Wang Z, Liu H, Zhu F, Li D . HawkDock: a web server to predict and analyze the protein-protein complex based on computational docking and MM/GBSA. Nucleic Acids Res. 2019; 47(W1):W322-W330. PMC: 6602443. DOI: 10.1093/nar/gkz397. View